Acurx Pharmaceuticals Analyst Ratings
Acurx Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 277.91% | HC Wainwright & Co. | → $13 | Reiterates | Buy → Buy |
| 09/13/2023 | 277.91% | HC Wainwright & Co. | → $13 | Reiterates | Buy → Buy |
| 08/15/2023 | 277.91% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 05/15/2023 | 306.98% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 04/11/2023 | 306.98% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 03/17/2023 | 306.98% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 12/19/2022 | 306.98% | HC Wainwright & Co. | → $14 | Initiates Coverage On | → Buy |
| 10/20/2022 | 306.98% | Alliance Global Partners | → $14 | Initiates Coverage On | → Buy |
| 11/29/2021 | 248.84% | Maxim Group | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/15/2023 | 277.91% | HC Wainwright & Co. | → 13 美元 | 重申 | 購買 → 購買 |
| 09/13/2023 | 277.91% | HC Wainwright & Co. | → 13 美元 | 重申 | 購買 → 購買 |
| 08/15/2023 | 277.91% | HC Wainwright & Co. | 14 美元 → 13 美元 | 維護 | 買 |
| 05/15/2023 | 306.98% | HC Wainwright & Co. | → 14 美元 | 重申 | 購買 → 購買 |
| 04/11/2023 | 306.98% | HC Wainwright & Co. | → 14 美元 | 重申 | → 購買 |
| 03/17/2023 | 306.98% | HC Wainwright & Co. | → 14 美元 | 重申 | → 購買 |
| 2022 年 12 月 19 日 | 306.98% | HC Wainwright & Co. | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 10 月 20 日 | 306.98% | 聯盟全球合作伙伴 | → 14 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/29/2021 | 248.84% | Maxim 集團 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Acurx Pharmaceuticals (ACXP)?
Acurx Pharmicals（ACXP）的目標價格是多少？
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $13.00 expecting ACXP to rise to within 12 months (a possible 277.91% upside). 7 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月15日公佈了Acurx Pharmicals（納斯達克股票代碼：ACXP）的最新目標股價。該分析公司將目標股價定爲13.00美元，預計ACXP將在12個月內升至12個月內（可能上漲277.91％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Acurx Pharmaceuticals (ACXP)?
分析師對Acurx Pharmicals（ACXP）的最新評級是多少？
The latest analyst rating for Acurx Pharmaceuticals (NASDAQ: ACXP) was provided by HC Wainwright & Co., and Acurx Pharmaceuticals reiterated their buy rating.
HC Wainwright & Co. 提供了Acurx Pharmicals（納斯達克股票代碼：ACXP）的最新分析師評級，Acurx Pharmicals重申了買入評級。
When is the next analyst rating going to be posted or updated for Acurx Pharmaceuticals (ACXP)?
Acurx Pharmicals（ACXP）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acurx Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acurx Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Acurx Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Acurx Pharmicals的最新評級是在2023年11月15日公佈的，因此您應該預計下一個評級將在2024年11月15日左右公佈。
Is the Analyst Rating Acurx Pharmaceuticals (ACXP) correct?
分析師對Acurx Pharmicals（ACXP）的評級是否正確？
While ratings are subjective and will change, the latest Acurx Pharmaceuticals (ACXP) rating was a reiterated with a price target of $0.00 to $13.00. The current price Acurx Pharmaceuticals (ACXP) is trading at is $3.44, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Acurx Pharmicals（ACXP）評級得到了重申，目標股價爲0.00美元至13.00美元。Acurx Pharmicals（ACXP）目前的交易價格爲3.44美元，在分析師的預測區間內。